Nursing Homes: Improper Schizophrenia Diagnoses & Antipsychotic Use Alleged
Concerns are mounting over the potential for inappropriate medication practices within nursing homes, specifically regarding the use of antipsychotic drugs. A recent report from the Department of Health and Human Services (HHS) Inspector General reveals instances where residents were incorrectly diagnosed with schizophrenia, potentially to justify the prescription of these powerful medications and influence a facility’s publicly reported quality ratings. This raises questions about resident safety and the integrity of care provided in these facilities.
The Link Between Diagnosis and Drug Use
Antipsychotic drugs, while sometimes necessary, carry significant risks, particularly for elderly individuals with dementia. The Food and Drug Administration (FDA) has issued warnings about an increased risk of death associated with their use in this population. The HHS Inspector General’s review found that some nursing homes may be prioritizing behavioral control – for staff convenience – over resident well-being, using antipsychotics as a chemical restraint. The incentive to misdiagnose residents stems from the way quality measures are calculated. The Centers for Medicare & Medicaid Services (CMS) tracks the percentage of residents receiving antipsychotic drugs as a quality metric, impacting a nursing home’s star rating. Diagnosing a resident with schizophrenia exempts them from this calculation, artificially improving a facility’s score.
A Two-Part Investigation
The HHS Inspector General’s findings are part of a two-part series examining antipsychotic drug use in nursing homes. The second report specifically details how some nursing homes inappropriately diagnosed residents with schizophrenia to mask the misuse of antipsychotic drugs and inflate their star ratings. Medical directors were found to be involved in making these questionable diagnoses, effectively justifying the prescriptions.
What are Antipsychotics and Why the Concern?
Antipsychotic medications are primarily designed to treat conditions like schizophrenia and bipolar disorder, characterized by psychosis – a disconnect from reality. They perform by affecting neurotransmitters in the brain, chemicals that transmit signals between nerve cells. While effective for their intended purposes, these drugs have a range of potential side effects, including sedation, movement disorders, metabolic changes, and an increased risk of stroke. For individuals with dementia, who often experience behavioral disturbances like agitation or wandering, antipsychotics are not approved treatments and can worsen their condition. The FDA’s boxed warning highlights the increased mortality risk in this vulnerable population.
Beyond Diagnosis: Systemic Failures
The HHS Inspector General’s investigation didn’t stop at diagnostic inaccuracies. The review of 40 focused nursing home inspections revealed broader systemic issues. Pharmacists, for example, sometimes failed to identify potential medical concerns or recommend dose reductions. Inadequate policies and procedures within the nursing homes undermined safeguards designed to protect residents. Medical directors, who should be acting as advocates for patient safety, were found to be contributing to the problem by approving inappropriate prescriptions. The OIG has been raising concerns about antipsychotic drug use for years, prompting CMS to develop quality measures to track and discourage their overuse. Still, these measures appear to have created unintended consequences, incentivizing facilities to manipulate data rather than improve care.
What Does This Indicate for Residents and Families?
The findings are deeply concerning for residents and their families. Inappropriate antipsychotic use can lead to a decline in physical and cognitive function, increased falls, and a reduced quality of life. It’s crucial for families to be actively involved in their loved ones’ care, asking questions about all medications prescribed and advocating for non-pharmacological approaches to managing behavioral symptoms whenever possible. Non-pharmacological approaches include things like increased social interaction, music therapy, and creating a calming environment.
The Role of CMS and Future Oversight
CMS has taken steps to address the issue, including the development of quality measures and increased scrutiny of nursing home practices. However, the recent reports suggest that more robust oversight is needed. The HHS Inspector General’s findings will likely lead to further investigations and potential enforcement actions against facilities found to be engaging in inappropriate practices. The agency is also exploring ways to refine the quality measures to prevent manipulation and ensure they accurately reflect the quality of care provided.
Looking Ahead: Strengthening Safeguards
The HHS Inspector General’s work is ongoing. This is the first of a two-part series, and the second part will likely delve deeper into the specific cases of misuse and identify additional vulnerabilities in the system. The agency is also reviewing survey reports to examine the nature of citations related to antipsychotic drug use and identify factors contributing to inappropriate prescribing. The goal is to strengthen safeguards and ensure that nursing home residents receive the safe, effective, and appropriate care they deserve. Families should remain vigilant and advocate for their loved ones, and regulators must continue to prioritize resident safety and hold facilities accountable for their actions.